
AVEO Pharmaceuticals AVEO
Quartalsbericht 2022-Q3
hinzugefügt 07.11.2022
AVEO Pharmaceuticals DSO 2011-2026 | AVEO
DSO Jährlich AVEO Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 47.5 | 72.6 | 20.7 | 204 | 19.4 | 149 | 89 | 47.1 | 1.92 K | 391 | 16 |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.92 K | 16 | 271 |
DSO Vierteljährlich AVEO Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 28.1 | - | 49.6 | 46.8 | 37.7 | 32.4 | 27.2 | - | 2.76 | 5.49 | 6.45 | 195 | 5.79 | 212 | 132 | 186 | 112 | 638 | 152 | 447 | 7.95 | 105 | 25.8 | 738 | 94.5 | 486 | 215 | 118 | 27.9 | 3.16 K | 2.38 K | 1.86 K | 245 | 116 | 9.92 | 278 | 278 | 277 | 3.06 K | 121 | 1.85 K | 1 K | 1.48 K | 600 | 184 | 24.8 | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 3.16 K | 2.76 | 478 |
DSO anderer Aktien in der Pharmaeinzelhändler
| Name | DSO | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
AbCellera Biologics
ABCL
|
173 | $ 3.64 | -1.89 % | $ 1.09 B | ||
|
ADMA Biologics
ADMA
|
74.6 | $ 16.45 | 0.43 % | $ 3.92 B | ||
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
ANI Pharmaceuticals
ANIP
|
114 | $ 76.75 | 0.85 % | $ 1.48 B | ||
|
Apellis Pharmaceuticals
APLS
|
115 | $ 19.93 | -1.14 % | $ 2.51 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
20.6 | $ 0.83 | 4.23 % | $ 4.53 M | ||
|
Athersys
ATHX
|
22.6 | - | 3.77 % | $ 22.4 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M | ||
|
BioDelivery Sciences International
BDSI
|
115 | - | -4.8 % | $ 255 M | ||
|
Axsome Therapeutics
AXSM
|
105 | $ 163.82 | -0.14 % | $ 8.15 B | ||
|
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | ||
|
BridgeBio Pharma
BBIO
|
52.4 | $ 66.98 | 3.8 % | $ 12.8 B | ||
|
CymaBay Therapeutics
CBAY
|
182 | - | - | $ 3.45 B | ||
|
Avid Bioservices
CDMO
|
45.6 | - | - | $ 789 M | ||
|
Checkpoint Therapeutics
CKPT
|
6.83 | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
164 | - | -16.75 % | $ 25.8 M | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Clovis Oncology
CLVS
|
65.5 | - | -7.23 % | $ 13 M | ||
|
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | ||
|
BioMarin Pharmaceutical
BMRN
|
88.9 | $ 60.75 | 3.79 % | $ 11.7 B | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
CTI BioPharma Corp.
CTIC
|
52.1 | - | - | $ 1.2 B | ||
|
Cyclacel Pharmaceuticals
CYCC
|
81.5 K | - | -5.98 % | $ 34.1 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
3.66 K | - | -4.36 % | $ 27 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
60.8 | - | - | $ 2.18 B | ||
|
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | ||
|
Capricor Therapeutics
CAPR
|
31.9 | $ 25.71 | -0.5 % | $ 688 M | ||
|
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | ||
|
Codexis
CDXS
|
32.9 | $ 1.1 | 12.24 % | $ 80.7 M | ||
|
Certara
CERT
|
89.6 | $ 7.33 | 1.24 % | $ 1.18 B | ||
|
Evofem Biosciences
EVFM
|
68.8 | - | 7.55 % | $ 38.1 M |